Pericyazine

TargetMol
Product Code: TAR-T16472
Supplier: TargetMol
CodeSizePrice
TAR-T16472-1mg1mg£101.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16472-2mg2mg£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16472-1mL1 mL * 10 mM (in DMSO)£127.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16472-5mg5mg£139.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16472-10mg10mg£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16472-25mg25mg£269.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16472-50mg50mg£399.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16472-100mg100mg£549.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T16472-500mg500mg£1,107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Pericyazine is a selective D2-dopamine receptor antagonist. Pericyazine is a first-generation antipsychotic drug that is used as an adjunct to the short-term management of severe anxiety states and psychosis.
CAS:
2622-26-6
Formula:
C21H23N3OS
Molecular Weight:
365.5
Pathway:
Neuroscience; GPCR/G Protein
Purity:
0.9936
SMILES:
OC1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C#N)CC1
Target:
Dopamine Receptor

References

1. Morley KC, et al. Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. Subst Abuse Rehabil. 2012 May 28;3:43-7. 2. Farde L, et al. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypicalneuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31. 3. Divac N, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.